These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 8682391

  • 1. [An epidemic of respiratory syncytial virus bronchiolitis among infants in northern Israel].
    Brik R, Ischah-Adiv A, Bentur L, Bar-Yosef G, Ben-Porath E, Efrath M.
    Harefuah; 1996 Feb 01; 130(3):161-4; 224, 223. PubMed ID: 8682391
    [Abstract] [Full Text] [Related]

  • 2. The severity of respiratory syncytial virus bronchiolitis in young infants in the United Arab Emirates.
    Howidi M, Rajah J, Abushrar Z, Parsons H.
    J Trop Pediatr; 2007 Feb 01; 53(1):22-6. PubMed ID: 17008442
    [Abstract] [Full Text] [Related]

  • 3. [Perinatal history and hospitalization for bronchiolitis. A comparison with the impact-RSV Study Group].
    Bonillo Perales A, DíezDelgado Rubio J, Ortega Montes A, Infante Márquez P, Jiménez Liria M, Batlles Garrido J, López Muñoz J.
    An Esp Pediatr; 2000 Dec 01; 53(6):527-32. PubMed ID: 11148149
    [Abstract] [Full Text] [Related]

  • 4. Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy.
    Bradley JP, Bacharier LB, Bonfiglio J, Schechtman KB, Strunk R, Storch G, Castro M.
    Pediatrics; 2005 Jan 01; 115(1):e7-14. PubMed ID: 15629968
    [Abstract] [Full Text] [Related]

  • 5. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
    Simoes EA, Carbonell-Estrany X.
    Pediatr Infect Dis J; 2003 Feb 01; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
    [Abstract] [Full Text] [Related]

  • 6. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA, Cosgrove JF, MacMahon P.
    Ir Med J; 2000 Dec 01; 93(9):284. PubMed ID: 11209917
    [Abstract] [Full Text] [Related]

  • 7. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T, Rozé JC, Fauroux B, French Pediatricians' Group of Sunagis Patients' Name-Based Programs.
    Pediatr Pulmonol; 2002 Sep 01; 34(3):181-8. PubMed ID: 12203846
    [Abstract] [Full Text] [Related]

  • 8. [Chemoprophylaxis with palivizumab in Andalusia (Spain). Results of the 2000-2001 respiratory syncytial virus epidemic].
    Grupo de Hospitales Benazuza.
    An Esp Pediatr; 2002 Apr 01; 56(4):293-7. PubMed ID: 11927095
    [Abstract] [Full Text] [Related]

  • 9. Respiratory syncytial virus infection in infants and young children.
    Levy BT, Graber MA.
    J Fam Pract; 1997 Dec 01; 45(6):473-81. PubMed ID: 9420581
    [Abstract] [Full Text] [Related]

  • 10. Ribavirin for respiratory syncytial virus bronchiolitis reduced the risk of asthma and allergen sensitization.
    Chen CH, Lin YT, Yang YH, Wang LC, Lee JH, Kao CL, Chiang BL.
    Pediatr Allergy Immunol; 2008 Mar 01; 19(2):166-72. PubMed ID: 18257904
    [Abstract] [Full Text] [Related]

  • 11. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep 01; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 12. Management and prevention strategies for respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a review of evidence-based practice interventions.
    Cooper AC, Banasiak NC, Allen PJ.
    Pediatr Nurs; 2003 Sep 01; 29(6):452-6. PubMed ID: 14743842
    [Abstract] [Full Text] [Related]

  • 13. [Severe bronchiolitis. Changes in epidemiology and respiratory support].
    Oñoro G, Pérez Suárez E, Iglesias Bouzas MI, Serrano A, Martínez De Azagra A, García-Teresa MA, Casado Flores J.
    An Pediatr (Barc); 2011 Jun 01; 74(6):371-6. PubMed ID: 21376684
    [Abstract] [Full Text] [Related]

  • 14. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation.
    Glanville AR, Scott AI, Morton JM, Aboyoun CL, Plit ML, Carter IW, Malouf MA.
    J Heart Lung Transplant; 2005 Dec 01; 24(12):2114-9. PubMed ID: 16364859
    [Abstract] [Full Text] [Related]

  • 15. Epidemiology of respiratory syncytial virus infection in northern Taiwan, 2001-2005 -- seasonality, clinical characteristics, and disease burden.
    Lee JT, Chang LY, Wang LC, Kao CL, Shao PL, Lu CY, Lee PI, Chen JM, Lee CY, Huang LM.
    J Microbiol Immunol Infect; 2007 Aug 01; 40(4):293-301. PubMed ID: 17712463
    [Abstract] [Full Text] [Related]

  • 16. [Clinical, therapeutic and developmental aspects of acute bronchiolitis in Tunisia].
    Ben Jaballah N, Mnif K, Hedfi L, Hammami A, Khaldi F, Bennaceur B.
    Cah Anesthesiol; 1996 Aug 01; 44(5):423-8. PubMed ID: 9183423
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The burden of respiratory syncytial virus bronchiolitis on a pediatric inpatient service.
    Eidelman AI, Megged O, Feldman R, Toker O.
    Isr Med Assoc J; 2009 Sep 01; 11(9):533-6. PubMed ID: 19960846
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection.
    Smith DW, Frankel LR, Mathers LH, Tang AT, Ariagno RL, Prober CG.
    N Engl J Med; 1991 Jul 04; 325(1):24-9. PubMed ID: 1904551
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.